Related Experiment Video

Updated: Jun 4, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

TFAP2A drives non-small cell lung cancer (NSCLC) progression and resistance to targeted therapy by facilitating the

Ding-Guo Wang1, Jian Gao2, Jing Wang1

  • 1Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Cell Death Discovery
|December 18, 2024
PubMed

Insights

Transcription factor AP-2 alpha (TFAP2A) is upregulated in non-small cell lung cancer (NSCLC) and promotes tumor progression. Targeting TFAP2A and ESR2 with PHTPP and osimertinib may offer a synergistic therapeutic strategy for NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer, particularly non-small cell lung cancer (NSCLC), presents a significant global health challenge with high mortality rates.
  • Transcription factors (TFs) play critical roles in gene regulation, and their dysregulation is implicated in various diseases, including cancer.
  • Understanding the specific roles of TFs like TFAP2A in NSCLC pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role and underlying mechanism of Transcription Factor AP-2 alpha (TFAP2A) in the development and progression of non-small cell lung cancer (NSCLC).
  • To identify potential molecular targets regulated by TFAP2A in NSCLC.
  • To explore therapeutic strategies targeting TFAP2A and its associated pathways.

Main Methods:

  • Comparative analysis of TFAP2A expression levels in NSCLC tumor tissues versus adjacent non-tumor tissues.
  • In vivo and in vitro experiments to assess the impact of TFAP2A overexpression on NSCLC progression.
  • Chromatin immunoprecipitation (ChIP) assays to determine TFAP2A binding to the ESR2 promoter region.
  • Analysis of MAPK signaling pathway activation in relation to TFAP2A and ESR2 expression.
  • Evaluation of the synergistic anti-tumor effect of PHTPP and osimertinib in NSCLC models.

Main Results:

  • TFAP2A expression was significantly elevated in NSCLC tumor tissues compared to para-tumor tissues.
  • High TFAP2A expression correlated with poor prognosis in NSCLC patients.
  • TFAP2A overexpression accelerated NSCLC progression in both in vivo and in vitro models.
  • TFAP2A directly binds to the promoter region of ESR2, suggesting ESR2 as a target gene.
  • Co-overexpression of TFAP2A and ESR2 was linked to overactivation of the MAPK signaling pathway.
  • Combined treatment with PHTPP and osimertinib demonstrated a synergistic effect in inhibiting tumor growth.

Conclusions:

  • TFAP2A is an oncogenic factor in NSCLC, promoting tumor progression and associated with poor patient outcomes.
  • TFAP2A regulates ESR2 expression, and their co-overexpression activates the MAPK pathway, contributing to NSCLC.
  • The combination of PHTPP and osimertinib shows promise as a synergistic therapeutic approach for NSCLC by targeting TFAP2A and ESR2-mediated signaling.

More Related Videos

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K